title: Transport and metabolism of the antitumour drug candidate 2'-benzoyloxycinnamaldehyde in Caco-2 cells.
abstract: The transport and metabolism of the antitumour drug candidate 2'-benzoyloxycinnamaldehyde (BCA) was characterized in Caco-2 cells. BCA disappeared rapidly from the donor side without being transported to the receiver side during its absorptive transport across Caco-2 cells. Its metabolites 2'-hydroxycinnamaldehyde (HCA) and o-coumaric acid (OCA) were formed in both the donor and the receiver sides. HCA, in a separate study, also disappeared rapidly from the donor side, mostly being converted to its oxidative metabolite OCA during its absorptive transport across Caco-2 cells. OCA was transported rapidly in the absorptive direction across Caco-2 cells with a P(app) of 25.4 +/- 1.0 x 10(-6) cm s(-1) (mean +/- standard deviation (SD), n = 3). OCA was fully recovered from both the donor and the receiver side throughout the time-course of this study. Formation of HCA from BCA was inhibited almost completely by bis(p-nitrophenyl)phosphate (BNPP), a selective inhibitor of carboxylesterases (CES), and phenylmethylsulfonyl fluoride (PMSF), a broad specificity inhibitor of esterases in Caco-2 cells, suggesting that this hydrolytic biotransformation was likely mediated predominantly by CES. Conversion of HCA to OCA was inhibited significantly by isovanillin, a selective inhibitor of aldehyde oxidase (AO). Inhibitors for xanthine oxidase (XO) and aldehyde dehydrogenase (ALDH), which are known to be involved in the oxidation of aldehydes to carboxylic acids, did not have a significant effect on the biotransformation of HCA to OCA in Caco-2 cells. In summary, the present work demonstrates that BCA is hydrolysed rapidly to HCA, followed by subsequent oxidation to OCA, in Caco-2 cells. The results provide a mechanistic understanding of the poor absorption and low bioavailability of BCA after oral administration.
authors.affiliation: Bio-Evaluation Center, KRIBB, Chungbuk, Republic of Korea.
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: S-K
authors.initials: SK
authors.lastname: Park
authors.forename: B-M
authors.initials: BM
authors.lastname: Kwon
authors.forename: K
authors.initials: K
authors.lastname: Kim
authors.forename: H E
authors.initials: HE
authors.lastname: Yu
authors.forename: J
authors.initials: J
authors.lastname: Ryu
authors.forename: S J
authors.initials: SJ
authors.lastname: Oh
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: J S
authors.initials: JS
authors.lastname: Kang
authors.forename: C W
authors.initials: CW
authors.lastname: Lee
authors.forename: M-G
authors.initials: MG
authors.lastname: Kwon
authors.forename: H M
authors.initials: HM
authors.lastname: Kim
mesh_terms: D000171:Acrolein / Q000031:analogs & derivatives* / Q000378:metabolism; D042931:Aldehyde Oxidase / Q000037:antagonists & inhibitors; D000970:Antineoplastic Agents / Q000378:metabolism*; D001565:Benzoates / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D018938:Caco-2 Cells; D003373:Coumaric Acids / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004950:Esterases / Q000037:antagonists & inhibitors; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D000432:Methanol / Q000494:pharmacology; D010084:Oxidation-Reduction / Q000187:drug effects; D013997:Time Factors
chemical_list: C484327:2'-benzoyloxycinnamaldehyde; D000970:Antineoplastic Agents; D001565:Benzoates; D003373:Coumaric Acids; D004791:Enzyme Inhibitors; D000171:Acrolein; D042931:Aldehyde Oxidase; D004950:Esterases; D000432:Methanol